Predict your next investment

Lupus Research Alliance company logo
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
lupusresearch.org

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

10

About Lupus Research Alliance

Lupus Research Alliance is a private funder of lupus research. Its goal is to improve treatments while advancing lupus research toward a cure.

Lupus Research Alliance Headquarter Location

275 Madison Avenue 10th Floor

New York, New York, 10016,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lupus Research Alliance

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lupus Research Alliance in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Lupus Research Alliance Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lupus Research Alliance Rank

Latest Lupus Research Alliance News

16:25 EDT LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis

Jul 27, 2022

News provided by Share this article Share this article NEW YORK, July 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults as well as lupus in the pediatric population. When proteins produced by the immune cells called antibodies attack the kidney tissue, inflammation, or lupus nephritis results. Eight out of ten children with lupus will have kidney damage, which usually stems from lupus nephritis. When the kidneys become inflamed, they can't effectively get rid of waste products and other toxins from the body. This can lead to end-stage kidney disease which can require dialysis to remove waste products mechanically or a kidney transplant. "Our community has much to celebrate with the approval of the first and much-needed treatment for children with lupus nephritis," commented Lupus Research Alliance President and CEO Kenneth M. Farber. "We are particularly proud to see belimumab approved to help yet another patient population, having funded much of the original research that led to the drug's development." Lupus nephritis has been a primary focus of lupus research since the organization's inception and continues with substantial investment going to improve diagnosis, monitoring, and treating the condition. Click here  for the announcement from GSK. About Lupus Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90 percent of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. African Americans, Hispanic Americans, Asian Americans and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints. About the Lupus Research Alliance The Lupus Research Alliance is the largest non-governmental, non-profit funder of lupus research worldwide. The organization aims to transform treatment by funding the most innovative lupus research, fostering diverse scientific talent, and driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs. SOURCE Lupus Research Alliance

Lupus Research Alliance Investments

1 Investments

Lupus Research Alliance has made 1 investments. Their latest investment was in CoImmune as part of their Grant on February 2, 2005.

CBI Logo

Lupus Research Alliance Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/24/2005

Grant

CoImmune

$1M

Yes

Date

2/24/2005

Round

Grant

Company

CoImmune

Amount

$1M

New?

Yes

Co-Investors

Sources

Lupus Research Alliance Portfolio Exits

1 Portfolio Exit

Lupus Research Alliance has 1 portfolio exit. Their latest portfolio exit was CoImmune on February 07, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/7/2014

IPO

$99M

Public

3

Date

2/7/2014

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

3

Lupus Research Alliance Partners & Customers

10 Partners and customers

Lupus Research Alliance has 10 strategic partners and customers. Lupus Research Alliance recently partnered with Juvenile Diabetes Research Foundation on February 2, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

2/24/2021

Partner

United States

First Joint Common Mechanisms Grants Announced. JDRF, Lupus Research Alliance and National Multiple Sclerosis Society Join Forces to Decode Common Mechanisms of Autoimmune Diseases - JDRF

`` JDRF is excited to partner with both the Lupus Research Alliance and the National MS Society to support this research and transform the lives of millions affected by these autoimmune and immune-mediated diseases . ''

2

2/24/2021

Partner

United States

National Multiple Sclerosis Society. JDRF, Lupus Research Alliance, and National MS Society Join Forces to Decode Common Mechanisms of Im

`` JDRF is excited to partner with both the Lupus Research Alliance and the National MS Society to support this research and transform the lives of millions affected by these autoimmune and immune-mediated diseases . ''

1

9/4/2020

Partner

United States

Contract Pharma Staff09.04.20. PPD, Lupus Therapeutics to Support Lupus Clinical Research. PPD, Lupus Therapeutics To Support Lupus Clinical Research - Contract Pharma

`` Lupus Therapeutics is an exemplary organization to collaborate with because of its extensive lupus expertise , '' said Karen Kaucic , M.D. , PPD , Inc. 's chief medical officer .

1

9/3/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/12/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

2/24/2021

2/24/2021

9/4/2020

9/3/2020

11/12/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

First Joint Common Mechanisms Grants Announced. JDRF, Lupus Research Alliance and National Multiple Sclerosis Society Join Forces to Decode Common Mechanisms of Autoimmune Diseases - JDRF

`` JDRF is excited to partner with both the Lupus Research Alliance and the National MS Society to support this research and transform the lives of millions affected by these autoimmune and immune-mediated diseases . ''

National Multiple Sclerosis Society. JDRF, Lupus Research Alliance, and National MS Society Join Forces to Decode Common Mechanisms of Im

`` JDRF is excited to partner with both the Lupus Research Alliance and the National MS Society to support this research and transform the lives of millions affected by these autoimmune and immune-mediated diseases . ''

Contract Pharma Staff09.04.20. PPD, Lupus Therapeutics to Support Lupus Clinical Research. PPD, Lupus Therapeutics To Support Lupus Clinical Research - Contract Pharma

`` Lupus Therapeutics is an exemplary organization to collaborate with because of its extensive lupus expertise , '' said Karen Kaucic , M.D. , PPD , Inc. 's chief medical officer .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.